Statistics for Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
Total visits
| views | |
|---|---|
| Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer | 75 |
Total visits per month
| views | |
|---|---|
| May 2024 | 0 |
| June 2024 | 0 |
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
File Visits
| views | |
|---|---|
| 41416_2020_Article_1041.pdf | 37 |
Top country views
| views | |
|---|---|
| United States | 65 |
| China | 1 |
| South Korea | 1 |
| Malaysia | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 42 |
| White Plains | 9 |
| Fairfield | 5 |
| Houston | 3 |
| Ann Arbor | 1 |
| Beijing | 1 |
| Cambridge | 1 |
| Concord | 1 |
| Seoul | 1 |
| Seremban | 1 |